How to Reconstitute BPC-157: Syringe Selection, Needle Gauge, and Step-by-Step Technique

What BPC-157 Is and Why Reconstitution Technique Matters

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a gastric protein sequence first characterized in human gastric juice. It is not FDA-approved for any indication as of January 2025, and the FDA has flagged BPC-157 as an unapproved drug substance that may not be compounded under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. That regulatory context matters, because it means the vials you are handling have no standardized manufacturer monograph and no USP-approved product monograph to fall back on.

Women are among the growing number of people seeking BPC-157 for tendon and ligament recovery, gut-lining support, and post-surgical healing. The evidence base is primarily animal data. A 2018 review in the Journal of Applied Physiology summarized animal studies showing accelerated tendon and ligament healing, but no randomized controlled trials in humans have been published as of this writing. That evidence gap is real, and it should anchor your expectations.

Reconstitution technique is not a minor detail. A syringe chosen incorrectly can cause unnecessary tissue trauma. The wrong diluent can degrade the peptide or introduce contamination. A dosing math error on a concentrated solution can produce a meaningfully different dose than intended. This guide covers all three of those failure points in detail.

Choosing the Right Diluent: Bacteriostatic Water vs. Sterile Water

Bacteriostatic water is the correct diluent for BPC-157. Full stop.

Why Bacteriostatic Water

Bacteriostatic water for injection (BAC water) contains 0.9% benzyl alcohol as a preservative. USP <1> General Notices and the USP <797> Pharmaceutical Compounding standards require that multi-dose reconstituted solutions include an antimicrobial preservative when beyond-use dating extends beyond 12 hours. Benzyl alcohol inhibits bacterial growth in the reconstituted vial across multiple draws, which is exactly what you need when one 5 mg vial may last 10 to 28 days of daily dosing.

Sterile water for injection contains no preservative. If you use it, USP <797> limits the beyond-use date of a reconstituted multi-dose preparation to 6 hours at room temperature or 24 hours refrigerated. A single-dose draw is the only safe use for sterile water. For a peptide protocol that spans weeks, sterile water creates contamination risk every time you re-enter the vial.

Benzyl Alcohol Allergy

Some women report hypersensitivity to benzyl alcohol. Signs include local injection-site burning beyond the usual brief sting, rash, or systemic flushing. If you have a documented allergy to benzyl alcohol, sterile water is the alternative, but you must prepare and use a fresh syringe within 24 hours of reconstitution, drawn from a vial that has not been previously punctured.

Does Benzyl Alcohol Degrade the Peptide?

Short-chain peptides can be sensitive to pH and oxidative stress. A 2019 stability analysis of synthetic peptide formulations in the journal Pharmaceutical Research found that benzyl-alcohol-preserved solutions maintained peptide integrity at 4°C for at least 28 days in the absence of strong oxidizing agents. BPC-157 has not been independently studied in the same format, so extrapolation is reasonable but not proven.

How Much Bacteriostatic Water to Use: Reconstitution Ratios

The volume of BAC water you add determines the concentration of your final solution, which in turn determines how many units on your insulin syringe correspond to a given dose.

The Standard 2 mL Ratio

Adding 2 mL of BAC water to a 5 mg (5,000 mcg) vial produces a concentration of 2,500 mcg per mL. On a U-100 insulin syringe, 1 mL equals 100 units, so:

• 1 unit = 25 mcg
• 2 units = 50 mcg
• 4 units = 100 mcg
• 8 units = 200 mcg
• 20 units = 500 mcg

This ratio is popular because the math is clean and the volumes (2-20 units for typical doses of 50-500 mcg) are large enough to draw accurately.

The 1 mL Ratio (High Concentration)

Adding 1 mL to a 5 mg vial yields 5,000 mcg/mL. Each unit on a U-100 syringe equals 50 mcg. This works if you are dosing 250-500 mcg and want smaller injection volumes, but it compresses dosing precision: a 1-unit error represents a 50 mcg mistake, which is a larger proportional error at low doses.

The 3 mL Ratio (Low Concentration)

Adding 3 mL yields approximately 1,667 mcg/mL. Each unit equals roughly 16.7 mcg. This is useful for very low doses (50-100 mcg) where precision matters most, because you are drawing 3-6 units rather than 2-4, giving you more room to be exact.

WomanRx Dosing Calculation Framework

| BAC Water Added | Concentration | 1 Unit (U-100 syringe) | Typical 250 mcg dose | |---|---|---|---| | 1 mL | 5,000 mcg/mL | 50 mcg | 5 units | | 2 mL | 2,500 mcg/mL | 25 mcg | 10 units | | 3 mL | 1,667 mcg/mL | ~16.7 mcg | ~15 units |

Choose your ratio based on your prescribed dose range and your comfort drawing small volumes accurately. Most women using 200-500 mcg daily will find the 2 mL ratio the most practical.

Syringe Selection: The Case for the Insulin Syringe

A U-100 insulin syringe is the standard instrument for peptide subcutaneous injection. Here is why it is preferred over other options, and when alternatives are appropriate.

Why U-100 Insulin Syringes

U-100 insulin syringes are calibrated in units (1-100) corresponding to 0.01 mL per unit. They are manufactured to tight tolerances because insulin dosing errors carry serious clinical consequences, which means the accuracy standards are high. They come preassembled with an integrated needle, eliminating a connection point that could introduce contamination or dead-space volume error.

They are also designed for subcutaneous tissue delivery: the needle length (5/16 inch, 8 mm, being the most common for adults) is appropriate for reaching the subcutaneous fat layer without penetrating muscle in most body regions.

Needle Gauge for Subcutaneous Injection

Gauge describes needle internal diameter. Higher numbers mean narrower bores.

• 28 gauge: Easy to draw, causes minimal pain, suitable for most peptide solutions. This is the most commonly recommended gauge for BPC-157 SubQ.
• 29-31 gauge: Finer bore, slightly slower draw, marginally less discomfort for people with needle sensitivity. Entirely appropriate for BPC-157 given its low viscosity.
• 27 gauge: Technically fine but unnecessarily wide for a water-like solution. No advantage over 28-31 for comfort.

A 2019 randomized crossover study in Diabetes Care evaluating needle gauge in subcutaneous injections found that 31-gauge needles produced significantly lower pain scores than 29-gauge at equivalent insertion depths, with no difference in absorption kinetics for water-soluble compounds. The study used insulin but the fluid-dynamics finding is applicable to low-viscosity peptide solutions.

For a woman with lower subcutaneous fat depth, such as someone with a low BMI or reduced fat mass associated with hypothalamic amenorrhea, a shorter needle (4-6 mm, 31 gauge) may be appropriate to avoid inadvertent intramuscular injection.

When Intramuscular Injection Is Used

Some practitioners prescribe BPC-157 intramuscularly for localized musculoskeletal applications, injecting near an injured site. For IM use, a 23-25 gauge, 1-1.5 inch needle is appropriate for most women. The syringe volume is typically 1-3 mL. A 3 mL luer-lock syringe with a detachable 23-gauge, 1-inch needle is the standard IM configuration for research peptide use.

USP <1> General Injection Guidelines specify that IM injections should target the ventrogluteal or vastus lateralis sites for volumes up to 2 mL in average-build adults, and that the deltoid should not receive volumes greater than 1 mL.

Step-by-Step Reconstitution Protocol

Clean technique is not optional. BPC-157 is injected, not swallowed, so contamination goes directly into your tissue or bloodstream.

What You Need Before You Start

• BPC-157 lyophilized powder vial
• Bacteriostatic water for injection (multi-dose vial)
• Alcohol swabs (70% isopropyl)
• One 1 mL U-100 insulin syringe (28-31 gauge) for drawing the BAC water
• A second 1 mL insulin syringe for your injection dose
• A clean, flat surface
• Refrigerator access (2-8°C) for storage

Reconstitution Steps

Step 1. Wash hands thoroughly with soap for at least 20 seconds. Dry with a clean paper towel.

Step 2. Swab the rubber septum of the BAC water vial with an alcohol swab. Let it air dry for 10 seconds. Do not fan or blow on it.

Step 3. Draw your target volume of BAC water into the insulin syringe. If you are using the 2 mL ratio, you will need to do two 1 mL draws or use a 3 mL syringe. Aim the needle tip toward the side of the vial rather than straight down to minimize foaming.

Step 4. Swab the rubber septum of the BPC-157 vial. Let dry.

Step 5. Insert the needle into the BPC-157 vial and angle the needle so the BAC water runs down the glass wall rather than directly onto the lyophilized cake. This minimizes mechanical disruption to the peptide structure.

Step 6. Do not shake the vial. Gently roll it between your palms for 15-30 seconds until the powder is fully dissolved. The solution should be clear and colorless. Any cloudiness, particulate matter, or pink or yellow discoloration means you should discard the vial.

Step 7. Label the vial with the date of reconstitution and the concentration you prepared. Store immediately at 2-8°C. Do not freeze.

Step 8. For each dose, swab the septum, draw your calculated volume into a fresh insulin syringe, and inject within 15-20 minutes of drawing.

Injection Site Selection for Women

Subcutaneous injection sites for BPC-157 follow the same anatomical guidance as insulin SubQ injections, with one addition: many women and practitioners prefer to inject near the site of injury or gut distress when using BPC-157 for localized or GI indications.

Common SubQ sites:

• Abdomen: 2 inches from the navel in any direction. Rotate within the region. Avoid the area directly around the navel.
• Thigh: Anterolateral aspect of the upper thigh. Suitable for self-injection.
• Flank or hip: Lateral hip fat pad. Less common but accessible.

Women in perimenopause and postmenopause often experience redistribution of subcutaneous fat toward the abdomen and away from the thigh and hip, which may make the abdominal site easier and more comfortable as estrogen declines. This is a practical consideration rather than a clinical contraindication.

Pinch the skin lightly, insert the needle at a 45-degree angle for shorter needles (4-6 mm) or 90 degrees for standard 8 mm needles in average-build women, deliver the dose slowly over 5-10 seconds, and withdraw smoothly. Applying light pressure with a clean gauze for 10 seconds after withdrawal reduces small hematoma formation, which is especially relevant for women on anticoagulants or NSAIDs.

BPC-157 and the Menstrual Cycle: What Is and Is Not Known

No published human trial has examined how the menstrual cycle affects BPC-157 pharmacokinetics or pharmacodynamics. This is an evidence gap you deserve to know about explicitly.

Animal models suggest BPC-157 acts partly through modulation of nitric oxide synthesis and prostaglandin pathways. A 2016 study in Current Pharmaceutical Design showed BPC-157 upregulated eNOS expression in a rat model of vascular injury. Prostaglandins are also central to menstrual physiology, and estrogen modulates eNOS activity across the cycle. Whether these overlapping pathways produce cycle-phase-dependent effects on BPC-157 efficacy or side-effect profile in women is unknown.

Women with PCOS, endometriosis, or hormonal-cycle-related gut symptoms (a common comorbidity with endometriosis) are among those exploring BPC-157 for its proposed gut-healing properties. There is no specific evidence to guide timing within the cycle for these groups. Until human data exist, consistent daily dosing at the same time each day is the practical default.

Pregnancy, Lactation, and Contraception

BPC-157 is not safe to use during pregnancy. Avoid it entirely if you are pregnant, trying to conceive, or not using reliable contraception.

No human pregnancy or lactation safety data exist for BPC-157. The compound has not been evaluated in teratogenicity studies under any regulatory framework. It is not assigned an FDA pregnancy category because it has not undergone FDA review.

Animal data from a 2018 rodent study in Current Neuropharmacology showed systemic BPC-157 exposure produced significant changes in nitric oxide and dopamine pathways. These systems are biologically active in early placental development and fetal neurodevelopment. That finding is not evidence of teratogenicity, but it is a reason for precaution in the complete absence of reassuring data.

Lactation transfer has not been studied. Benzyl alcohol, the preservative in your diluent, does transfer to breast milk in small amounts at the doses used in neonatal saline flushes. The American Academy of Pediatrics has flagged benzyl alcohol as a substance of concern in neonates, though harm from trace lactational exposure is not established. The combination of an unstudied peptide compound and a preservative with a neonatal concern profile means lactating women should not use reconstituted BPC-157.

If you are in your reproductive years and using BPC-157, use reliable contraception throughout the course of treatment.

Who This May Be Right For and Who Should Avoid It

Potentially Appropriate Candidates

• Women with documented tendon or ligament injuries seeking adjunct recovery support, who are not pregnant or lactating, who have discussed the off-label and unproven nature of the compound with a licensed provider
• Women with functional gut complaints (leaky gut, IBD-adjacent symptoms) who have exhausted evidence-based options and are working with a clinician who can monitor for adverse effects
• Perimenopausal or postmenopausal women with musculoskeletal pain syndromes, noting that the evidence is animal-derived and extrapolation to this population is speculative

Women Who Should Avoid BPC-157

• Any woman who is pregnant, attempting pregnancy, or not using reliable contraception
• Lactating women
• Women with active malignancy or a history of hormone-sensitive cancers: BPC-157 promotes angiogenesis in animal models, and the clinical implications of this for cancer biology are unknown
• Women with a documented benzyl alcohol allergy who cannot reliably manage single-use sterile water preparations
• Women currently taking anticoagulants, unless injection-site hematoma risk has been discussed with their prescriber

Storage, Stability, and Signs of Degradation

Reconstituted BPC-157 should be stored at 2-8°C (standard refrigerator temperature). Do not freeze: freeze-thaw cycles disrupt peptide secondary structure. Peptide stability research published in the European Journal of Pharmaceutics and Biopharmaceutics consistently shows that freeze-thaw cycling is among the primary causes of aggregation and potency loss in synthetic peptide formulations.

Beyond-use date with benzyl-alcohol-preserved BAC water: 28 days refrigerated. Beyond-use date with sterile water: 24 hours refrigerated.

Discard the vial if you see:

• Any cloudiness or visible particulate
• Color change from clear to yellow, pink, or brown
• A precipitate that does not dissolve with gentle rolling
• Any crack or breach in the rubber septum

Write the reconstitution date directly on the vial label with a marker. Do not rely on memory.

FAQs